European PE firm Apax Partners has acquired a majority stake in Porsolt, a global CRO. Apax’s investment, together with that of the management and current shareholders, will allow Porsolt to further grow and implement its strategy to become a comprehensive preclinical service company, addressing the varying therapeutical areas of the global pharma, biotech, and research…